Cargando…

Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer

Detalles Bibliográficos
Autores principales:	Rizzo, Alessandro, Mollica, Veronica, Santoni, Matteo, Massari, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658344/ https://www.ncbi.nlm.nih.gov/pubmed/36362584 http://dx.doi.org/10.3390/jcm11216356

Ejemplares similares

Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution
por: Rizzo, Alessandro, et al.
Publicado: (2021)

The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer
por: Mollica, Veronica, et al.
Publicado: (2020)

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Is There a Role for Immunotherapy in Prostate Cancer?
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis
por: Righini, Matteo, et al.
Publicado: (2022)

The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT
por: Mollica, Veronica, et al.
Publicado: (2021)

Treating Prostate Cancer by Antibody–Drug Conjugates
por: Rosellini, Matteo, et al.
Publicado: (2021)

Harnessing the Immune System to Fight Multiple Myeloma
por: Krejcik, Jakub, et al.
Publicado: (2021)

N-Myc a key gene promoting a worst prostate cancer progression
por: Di Nunno, Vincenzo, et al.
Publicado: (2019)

Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Harnessing of Programmed Necrosis for Fighting against Cancers
por: Cho, Young Sik, et al.
Publicado: (2014)

Harnessing epithelial homeostatic mechanisms to fight cancer
por: Lahvic, Jamie L., et al.
Publicado: (2019)

Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy
por: Subhash, Vinod Vijay, et al.
Publicado: (2015)

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022)

Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views
por: Aurilio, Gaetano, et al.
Publicado: (2021)

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications
por: Santoni, Matteo, et al.
Publicado: (2018)

Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
por: Mollica, Veronica, et al.
Publicado: (2021)

Moving ahead on harnessing synthetic lethality to fight cancer
por: Jerby-Arnon, Livnat, et al.
Publicado: (2015)

Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
por: Mollica, Veronica, et al.
Publicado: (2022)

PARP inhibition and immunotherapy: a promising duo in fighting cancer
por: Phillipps, Jordan, et al.
Publicado: (2023)

Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients’ care
por: Massari, Francesco, et al.
Publicado: (2020)

The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
por: Marchetti, Andrea, et al.
Publicado: (2021)

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
por: Mollica, Veronica, et al.
Publicado: (2021)

Harnessing the Microbiome to Enhance Cancer Immunotherapy
por: Nelson, Michelle H., et al.
Publicado: (2015)

Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer
por: Mollica, Veronica, et al.
Publicado: (2019)

TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?—a narrative review
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough
por: Mollica, Veronica, et al.
Publicado: (2021)

Harnessing the power of antibodies to fight bone metastasis
por: Tian, Zeru, et al.
Publicado: (2021)

Radiation and immunotherapy: united as one in the fight against cancer
por: Amini, Arya, et al.
Publicado: (2021)

Engineering Viruses to Fight Cancer
Publicado: (2016)

The Fight Against Cervical Cancer
Publicado: (2015)

Harnessing the antitumor potential of macrophages for cancer immunotherapy
por: Long, Kristen B, et al.
Publicado: (2013)

Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy
por: Yan, Liang, et al.
Publicado: (2021)

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
por: Mollica, Veronica, et al.
Publicado: (2020)

Genomics and Immunomics in the Treatment of Urothelial Carcinoma
por: Mollica, Veronica, et al.
Publicado: (2022)

Narrative review: update on immunotherapy and pathological features in patients with bladder cancer
por: Aurilio, Gaetano, et al.
Publicado: (2021)

Case reports and the fight against cancer
por: Dib, Elie G, et al.
Publicado: (2008)

Peptidergic Systems as Antitumor Targets: A Right Direction to Fight Cancer?
por: Rodríguez, Francisco D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b9m0p84r2sch11gadjvffdqnmb